Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG) in Patients With Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma

Next Previous
Trial Profile

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG) in Patients With Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belzutifan (Primary) ; HC-7366 (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors HiberCell

Most Recent Events

  • 27 May 2025 According to a HiberCell media release, company announced the successful completion of the dose escalation portion of its Phase 1b study evaluating HC-7366, The dose escalation phase enrolled 18 patients.
  • 27 May 2025 According to a HiberCell media release, company announced that enrollment in the 40 mg expansion cohort is now complete. Enrollment for the 60 mg cohort is ongoing and is expected to complete before the end of the second quarter of 2025. Each expansion cohort is designed to enroll 15 patients. In parallel, a separate cohort evaluating HC-7366 as monotherapy at the 60 mg dose is also actively enrolling patients.
  • 01 May 2024 According to HiberCell media release, first patient had been dosed in this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top